A recent study described an attempt at CRISPR/Cas9-mediated knockout of VHL in RENCA, but the resulting variant suffered from variable tumour take and immune-mediated rejection after implantation in BALB/c mice.54 With regards to the EMT-6/CDDP model, this particular variant was chosen for its increased incidence of postsurgical metastases compared to its parental line, as mentioned above. Here, VHL is linked to neoplasm.